Holen Sie sich die Stockscreener-App
26.68
0.37%
-0.10
Handel nachbörslich:
26.68
Schlusskurs vom Vortag:
$26.78
Offen:
$27.02
24-Stunden-Volumen:
412.70K
Relative Volume:
0.66
Marktkapitalisierung:
$1.98B
Einnahmen:
$105.97M
Nettoeinkommen (Verlust:
$-81.13M
KGV:
-24.72
EPS:
-1.0791
Netto-Cashflow:
$-35.43M
1W Leistung:
-4.51%
1M Leistung:
+3.41%
6M Leistung:
+47.81%
1J Leistung:
+107.63%
1-Tages-Spanne:
$26.12
$27.33
1-Wochen-Bereich:
$26.12
$28.18
52-Wochen-Spanne:
$10.86
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.68 | 1.99B | 105.97M | -81.13M | -35.43M | -1.0791 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME - MarketBeat
Kornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYME - MarketBeat
H.C. Wainwright reiterates Zymeworks stock rating on FDA filing By Investing.com - Investing.com India
Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
H.C. Wainwright reiterates Zymeworks stock rating on FDA filing - Investing.com UK
Zymeworks (NASDAQ:ZYME) Raised to Strong-Buy at Truist Financial - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 52-Week HighTime to Buy? - MarketBeat
HC Wainwright & Co. Upgrades Zymeworks (ZYME) - MSN
Zymeworks appoints Kristin Stafford as CFO - MSN
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera - Yahoo Finance
Zymeworks stock hits 52-week high at $28.50 By Investing.com - Investing.com India
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighWhat's Next? - MarketBeat
Zymeworks stock hits 52-week high at $28.50 - Investing.com
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - wahanariau.com
Stifel reiterates Zymeworks stock rating on ADC data strength - Investing.com UK
Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa
PERCEPTIVE ADVISORS LLC Expands Stake in Zymeworks Inc with Sign - GuruFocus
Zymeworks reports phase 1 trial results for ovarian cancer drug - Investing.com
Zymeworks (ZYME) Broadens ADC Toolkit at AACR 2026 Is Its Oncology Platform Taking Shape? - simplywall.st
Experimental Zymeworks cancer drug shows 61% response in ovarian study - Stock Titan
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace
Zymeworks Inc stock (US98985W1080): Is its bispecific antibody platform resilient enough for biotech - AD HOC NEWS
A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention - Sahm
Zymeworks presents preclinical data on ADC pipeline at AACR By Investing.com - Investing.com Australia
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform - wahanariau.com
Zymeworks presents preclinical data on ADC pipeline at AACR - Investing.com
Zymeworks Inc. - Via Ritzau
Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN
Zymeworks Inc. (ZYME) Stock Analysis: Robust Buy Ratings And Promising Upside Potential - DirectorsTalk Interviews
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 - Sahm
How Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And Deals - Yahoo Finance
Cancer meeting data show Zymeworks testing targeted drugs for RAS tumors - Stock Titan
Zymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline Update - TipRanks
Perceptive-linked holders report 3.97M shares of Zymeworks (ZYME) - Stock Titan
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline strategy is suddenly worth a closer l - AD HOC NEWS
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN
How Investors Are Reacting To Zymeworks (ZYME) Elevating EcoR1 Veterans To Key Executive Roles - simplywall.st
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline is suddenly worth a closer look - AD HOC NEWS
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):